Matches in Wikidata for { <http://www.wikidata.org/entity/Q91162700> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q91162700 description "article scientifique publié en 2019" @default.
- Q91162700 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91162700 description "scientific article published on 07 November 2019" @default.
- Q91162700 description "wetenschappelijk artikel" @default.
- Q91162700 description "наукова стаття, опублікована 7 листопада 2019" @default.
- Q91162700 name "Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity" @default.
- Q91162700 name "Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity" @default.
- Q91162700 type Item @default.
- Q91162700 label "Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity" @default.
- Q91162700 label "Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity" @default.
- Q91162700 prefLabel "Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity" @default.
- Q91162700 prefLabel "Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity" @default.
- Q91162700 P1433 Q91162700-B21E83CC-0A4A-458C-9F25-8EECC7DEA332 @default.
- Q91162700 P1476 Q91162700-BE1A4EF9-79B2-40EF-A1F3-A8756ECE47C2 @default.
- Q91162700 P2093 Q91162700-1A2279C4-2AE3-4623-A154-25B41E6E54C2 @default.
- Q91162700 P2093 Q91162700-3FE7F117-1B77-4199-BD7A-20CA39FB8F75 @default.
- Q91162700 P2093 Q91162700-5A51FE04-D1B3-43ED-B0FD-A63C52133ECE @default.
- Q91162700 P2093 Q91162700-6AB6E47D-67F6-4408-8A2C-5F258E66CFD0 @default.
- Q91162700 P2093 Q91162700-7BF3DA65-BE5D-4F24-86F0-D82721EDAAEE @default.
- Q91162700 P2093 Q91162700-B1C70141-37B3-4E4A-BAD9-D589376430A4 @default.
- Q91162700 P2093 Q91162700-B8A06AA4-94BE-4A88-BF56-265F9D9EEF9D @default.
- Q91162700 P2093 Q91162700-C3AF47AF-03F1-4B50-8DE1-BBC92BFB0876 @default.
- Q91162700 P2093 Q91162700-E8915FD6-B460-4246-AF7B-86115F1617CA @default.
- Q91162700 P31 Q91162700-D8BF1649-5B75-4DB3-BF39-8A6CE45EAD76 @default.
- Q91162700 P356 Q91162700-BC6910B3-3CDE-4D2D-9B4B-43AE46EAF030 @default.
- Q91162700 P50 Q91162700-3CFA8568-BF6A-439D-9A70-9657E7728057 @default.
- Q91162700 P50 Q91162700-98DFEABC-CE18-4345-9BDF-22537A5C5279 @default.
- Q91162700 P577 Q91162700-6C488239-7598-421D-8EF1-02F24D4C3008 @default.
- Q91162700 P698 Q91162700-EC560A1A-6C57-4920-92FF-095E96A16450 @default.
- Q91162700 P921 Q91162700-9EEAC006-2686-465D-B068-3AF17E40C469 @default.
- Q91162700 P921 Q91162700-C0013542-29B9-422E-9799-FACB2FE90C39 @default.
- Q91162700 P932 Q91162700-D90AA1A1-8A0E-4978-9F06-ABC41F206AEB @default.
- Q91162700 P356 JAMAOPHTHALMOL.2019.4488 @default.
- Q91162700 P698 31697304 @default.
- Q91162700 P1433 Q4787301 @default.
- Q91162700 P1476 "Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity" @default.
- Q91162700 P2093 "David K Wallace" @default.
- Q91162700 P2093 "Don L Bremer" @default.
- Q91162700 P2093 "Eric R Crouch" @default.
- Q91162700 P2093 "Janine E Collinge" @default.
- Q91162700 P2093 "Jonathan M Holmes" @default.
- Q91162700 P2093 "Michael E Gray" @default.
- Q91162700 P2093 "Paul G Steinkuller" @default.
- Q91162700 P2093 "Raymond T Kraker" @default.
- Q91162700 P2093 "Writing Committee for the Pediatric Eye Disease Investigator Group" @default.
- Q91162700 P31 Q13442814 @default.
- Q91162700 P356 "10.1001/JAMAOPHTHALMOL.2019.4488" @default.
- Q91162700 P50 Q112977553 @default.
- Q91162700 P50 Q89701344 @default.
- Q91162700 P577 "2019-11-07T00:00:00Z" @default.
- Q91162700 P698 "31697304" @default.
- Q91162700 P921 Q1423087 @default.
- Q91162700 P921 Q413299 @default.
- Q91162700 P932 "6865236" @default.